ASCO 2026: Updated Phase III Data Support Daromun in Resectable Melanoma

With 36.8 months of follow-up, updated Phase III data confirm significant improvements in relapse-free and distant metastasis-free survival with neoadjuvant intralesional daromun (L19IL2/L19TNF) in resectable locally advanced melanoma. PD Dr. med. Katharina C. Kähler, Head of the Skin Cancer Unit at the University of Kiel, reviews the primary outcome update, EFS analyses and subgroup findings.